Introduction
============

Infections remain a major cause of morbidity and mortality in neutropenic patients. Although recent data on the routes of infection are inconsistent, it is assumed that the majority of bacterial infections is caused by endogenous organisms or acquired Gram-negative bacteria which colonize the gastrointestinal tract \[[@R1]\]. Therefore, prophylactic selective bowel decontamination (SBD) using non-absorbable antibacterial and antifungal agents is applied in patients undergoing bone marrow transplantation in some hospitals, although the value of this measure is controversial \[[@R2]\], \[[@R3]\]. Like other aminoglycoside compounds, paromomycin (aminosidine) is poorly absorbed from the gastrointestinal tract \[[@R4]\]. This compound is in use for SBD in some centers \[[@R2]\], \[[@R5]\], \[[@R6]\].

However, in vitro resistance data for paromomycin are lacking. Previously, we have published the observation that bacteremia with enterobacteriaceae is observed less frequently in neutropenic patients with previous SBD using paromomycin, whereas there is no difference with regard to bacteremia with non-fermenting Gram-negative bacilli \[[@R6]\]. In this context, the aim of the present study was to investigate the in vitro activity of paromomycin against *E. coli* and *P. aeruginosa*.

Material and methods
====================

*E. coli*isolates (n=94) were obtained from stool/rectal swabs (n=69), urine (n=10), respiratory tract (n=9), blood (n=4), and wound swabs (n=2). *P. aeruginosa* isolates (n=77) were derived from stool/rectal swabs (n=5), respiratory tract (n=6), blood (n=60), and wound swabs (n=6). Identification was performed with API™ 20E (BioMérieux, Marcy L'Etoile, France) for *E. coli*, and with culture on cetrimide agar plates (Pseudosal™; Becton Dickinson, Heidelberg, Germany) and inspection under UV-light combined with API™ 20NE (BioMérieux) for *P. aeruginosa.*

Amikacin and paromomycin were purchased from Sigma Aldrich (Steinheim, Germany). The MICs for both compounds were determined according to the recommendations of the Clinical Laboratory Standards International (CLSI) for testing amikacin \[[@R7]\]. Isolates with an MIC of ≤16 µg/ml were considered susceptible. The ATCC reference strains 25922 (*E. coli*) and 9027 (*P. aeruginosa*) were used for quality control.

Results
=======

The MICs for paromomycin and amikacin against *E. coli* and *P. aeruginosa*, respectively, are shown in Table 1 [(Tab. 1)](#T1){ref-type="fig"}.

Briefly, 86 of 94 *E. coli* isolates (91%) and 71 of 77 *P. aeruginosa* isolates (92%) showed in vitro susceptibility to amikacin (MIC90 for both compounds: 16 µg/ml, range: 1--32 µg/ml for*E. coli* and 1--\>128 µg/ml for*P. aeruginosa*). Paromomycin was active against 83/94 *E. coli* isolates (88%; MIC90: 32 µg/ml, range: 2--\>128 µg/ml), but showed poor in vitro activity against *P. aeruginosa* (3/77 isolates susceptible \[4%\]; MIC90: \>128 µg/ml, range: 2--\>128 µg/ml).

Discussion
==========

Paromomycin, which was first isolated in 1956, is a member of the aminoglycoside family. The agent inhibits protein synthesis and the assembly of the 30S ribosomal subunit \[[@R8]\]. Paromomycin is indicated for the treatment of *Entamoeba histolytica* and *Trichomonas* spp. infections, and has been proposed as a treatment for *Giardia lamblia* in resistant infections and during pregnancy \[[@R9]\]. Furthermore, it is used for prophylaxis of hepatic encephalopathy in patients with liver cirrhosis. Paromomycin is also used for SBD in patients undergoing bone marrow transplantation in some centers \[[@R2]\], \[[@R5]\], \[[@R6]\]. In addition, paromomycin is frequently recommended for the use in SBD by non-peer reviewed media, at least in the German-speaking countries. Amikacin resistance in *E. coli* and *P. aeruginosa* was found to be in agreement with previously published data in the present study is. An analysis of more than 4,000 clinical isolates from patients with bloodstream infections in the United States revealed that 98.5% of *E. coli* isolates and 98.4% of *P. aeruginosa* isolates were susceptible to this agent \[[@R10]\]. 94.4% of *P. aeruginosa* blood culture isolates in Vienna University Hospital are susceptible to amikacin \[[@R11]\].

Due to the lack of published in vitro resistance data for paromomycin, no trend in paromomycin resistance can be deduced from the present results. In addition, it is unknown which mechanisms lead to clinically relevant resistance against paromomycin. Generally, bacterial resistance to aminoglycosides may be due to decreased antibiotic uptake and accumulation, modification of the ribosomal target, and efflux of the antibiotic, but the enzymatic modification of aminoglycosides is thought to be the most important mechanism of aminoglycoside resistance in clinical isolates \[[@R12]\]. Three families of enzymes that perform cofactor-dependent drug modification in the bacterial cytoplasm have been recognized; these are aminoglycoside phosphotransferases (APHs), aminoglycoside acetyltransferases (AACs), and aminoglycoside nucleotidyltransferases (ANTs). Some enzymes (i.e. APH(3\')-I, APH(3\')-III, and AAC(1)) have been shown to produce paromomycin resistance, while they are not implicated in amikacin resistance \[[@R12]\].

Conclusions
===========

In conclusion, if SBD with inclusion of an aminoglycoside antibiotic is applied, paromomycin should not be used unless local resistance data provide evidence of a sufficient in vitro activity of this compound against *P. aeruginosa*.
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